ReviewInternational journal of nephrology2025
Circulating Muscle Markers for Sarcopenia in Peritoneal Dialysis.
Review in International journal of nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenia, characterized by the progressive decline in muscle mass and function, is an important complication among patients undergoing peritoneal dialysis (PD). Despite its prevalence, there is a notable lack of comprehensive research focused on early diagnosis or treatment target for sarcopenia in PD patients. This review explores the pathophysiology of sarcopenia and examines the potential role of various biomarkers related to muscle mass and function. These markers include myokines (cytokines produced by skeletal muscle) such as myostatin, follistatin, activin A, growth differentiation factor 15 (GDF-15), and irisin, as well as adiponectin, leptin, insulin-like growth factor-1 (IGF-1), vitamin D, myoglobin, and cortisol. These markers hold promise for early diagnosis and as therapeutic targets for managing sarcopenia. By reviewing the current literature in this area, we aim to identify directions for further research on diagnostic strategies and therapeutic options for sarcopenic PD patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.